Payment overview · 2025
General Payments
$6,769.59
127 reported records · 22 companies
Healthcare provider profile · identity verified
Fred Revoredo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PATERSON, NJ · NPI 1669588422
Verified facts
What the public records show
CMS Open Payments records show Fred Revoredo, M.D. received $6,769.59 in general payments during 2025 across 127 reported records.
Medtronic, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Rexulti, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,454.62 | 21.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,045.77 | 15.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $995.38 | 14.7% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $678.21 | 10.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $527.25 | 7.8% | 22 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $381.35 | 5.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $316.43 | 4.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $274.26 | 4.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $214.54 | 3.2% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $158.47 | 2.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $130.42 | 1.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $122.92 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $89.33 | 1.3% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $88.41 | 1.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.39 | 1.1% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $50.27 | 0.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.76 | 0.7% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.51 | 0.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.36 | 0.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.53 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.40 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.01 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,960.51 | 124 |
| Travel and Lodging | $809.08 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $1,454.62 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $527.25 | 22 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $521.90 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $400.31 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $342.28 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $316.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $306.40 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $276.53 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $274.26 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $259.74 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $246.83 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $244.02 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $214.54 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $181.42 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $158.47 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $155.81 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $143.45 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $143.40 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $130.42 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $122.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $113.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $89.33 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $69.42 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $63.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.43 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $50.27 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.76 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 352 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 193 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 245 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
193 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
352 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
352 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
128 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
245 | 62 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 810 | 250 |
| Metformin Hcl | Metformin Hcl | 774 | 243 |
| Alprazolam | Alprazolam | 721 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 703 | 214 |
| Diclofenac Sodium | Diclofenac Sodium | 673 | 212 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 611 | 143 |
| Donepezil Hcl | Donepezil Hcl | 571 | 191 |
| Memantine Hcl | Memantine Hcl | 498 | 163 |
| Omeprazole | Omeprazole | 439 | 119 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 418 | 57 |
| Jardiance | Empagliflozin | 352 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 350 | 117 |
| Ibuprofen | Ibuprofen | 324 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 89 |
| Simvastatin | Simvastatin | 299 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 94 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 259 | 72 |
| Ozempic | Semaglutide | 245 | 62 |
| Gabapentin | Gabapentin | 239 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 230 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 224 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 220 | 73 |
| Lisinopril | Lisinopril | 215 | 79 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 202 | 63 |
| Furosemide | Furosemide | 200 | 65 |
| Alendronate Sodium | Alendronate Sodium | 193 | 69 |
| Linzess | Linaclotide | 193 | 63 |
| Cefdinir | Cefdinir | 184 | 128 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 184 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 57 |
| Finasteride | Finasteride | 182 | 63 |
| Glimepiride | Glimepiride | 181 | 52 |
| Oxycodone Hcl | Oxycodone Hcl | 180 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 54 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 159 | 55 |
| Januvia | Sitagliptin Phosphate | 159 | 31 |
| Sertraline Hcl | Sertraline Hcl | 148 | 51 |
| Tramadol Hcl | Tramadol Hcl | 144 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 142 | 55 |
| Nifedipine Er | Nifedipine | 132 | 36 |
| Trulicity | Dulaglutide | 128 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 56 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 127 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 125 | 55 |
| Meclizine Hcl | Meclizine Hcl | 124 | 56 |
| Famotidine | Famotidine | 121 | 42 |
| Megestrol Acetate | Megestrol Acetate | 120 | 42 |
| Hydrocortisone | Hydrocortisone | 119 | 63 |
| Losartan Potassium | Losartan Potassium | 115 | 39 |
| Azithromycin | Azithromycin | 112 | 83 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 108 | 33 |
| Ammonium Lactate | Ammonium Lactate | 104 | 40 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 102 | 30 |
| Levofloxacin | Levofloxacin | 102 | 79 |
| Clonidine Hcl | Clonidine Hcl | 101 | 26 |
| Clonazepam | Clonazepam | 99 | 19 |
| Montelukast Sodium | Montelukast Sodium | 98 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 79 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 28 |
| Celecoxib | Celecoxib | 93 | 47 |
| Endocet | Oxycodone Hcl/Acetaminophen | 92 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 78 | 29 |
| Prednisone | Prednisone | 73 | 49 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 21 |
| Metronidazole | Metronidazole | 70 | 52 |
| Farxiga | Dapagliflozin Propanediol | 69 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 16 |
| Meloxicam | Meloxicam | 68 | 36 |
| Eliquis | Apixaban | 64 | 18 |
| Carvedilol | Carvedilol | 63 | 17 |
| Vascepa | Icosapent Ethyl | 61 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 60 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 19 |
| Procto-Med Hc | Hydrocortisone | 57 | 21 |
| Single Use Swab | Alcohol Antiseptic Pads | 57 | suppressed |
| Allopurinol | Allopurinol | 55 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | 12 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Acyclovir | Acyclovir | 42 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Naproxen | Naproxen | 39 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Promethazine Hcl | Promethazine Hcl | 36 | 24 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 24 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 35 | 27 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 13 |
| Lactulose | Lactulose | 34 | 13 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 34 | 23 |
| Enalapril Maleate | Enalapril Maleate | 33 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 19 |
| Colchicine | Colchicine | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | 12 |
| Mupirocin | Mupirocin | 28 | 19 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Ibu | Ibuprofen | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Mupirocin | Mupirocin Calcium | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 17 |
| Terconazole | Terconazole | 23 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | 11 |
| Valsartan | Valsartan | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 11 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultracare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Mitigare | Colchicine | 15 | suppressed |
| Verquvo | Vericiguat | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Nicotrol | Nicotine | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,769.59 · 127 records | Medtronic, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, JARDIANCE, Korlym, LINZESS, LOREEV XR, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TZIELD, UBRELVY, VERQUVO, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error